Equine IFN beta Polyclonal Antibody

The Equine IFN beta polyclonal antibody is unlabeled and has been qualified for use in ELISA and Western blot applications. It is the capture antibody in the Kingfisher Biotech Equine IFN beta ELISA. The Equine IFN beta antibody was produced in rabbits and is antigen-affinity purified. The reactivity by species is: (Bovine IFN-beta - Weak) (Equine IFN-beta1 - Strong) (Mouse IFN-beta - Weak) (Swine IFN-beta - Weak). For research use only.

Equine Interferon-Beta (IFN-β) is a type I interferon produced primarily by virus-infected epithelial cells, fibroblasts, macrophages, and dendritic cells in horses (Equus caballus), where it serves as a key early mediator of innate antiviral immunity. Following recognition of viral nucleic acids by pattern recognition receptors such as RIG-I-like receptors and the cGAS-STING pathway, equine IFN-β is rapidly induced and signals through the type I interferon receptor complex (IFNAR1/IFNAR2), activating JAK/STAT signaling and promoting expression of interferon-stimulated genes (ISGs) that suppress viral replication, enhance antigen presentation, and stimulate natural killer (NK) cell and adaptive immune responses. IFN-β is critically involved in host defense against important equine viral pathogens including equine influenza virus, equine herpesvirus-1 and -4 (EHV-1/EHV-4), West Nile virus, and equine arteritis virus, and the timing and magnitude of IFN-β production can influence viral control, inflammation, and clinical outcome. Viral evasion or dysregulation of IFN-β signaling may contribute to persistent infection or immunopathology. In veterinary and translational research, characterization of equine IFN-β supports studies of respiratory and neurotropic viral pathogenesis, antiviral therapeutics, vaccine development, and comparative type I interferon biology in large-animal models relevant to both equine and human infectious disease research.

Choose a size

Please choose a size to see price

RELATED MEDIA